

Complete List of Publications

36. Iamshanova O, Mariot P, **Lehen'kyi V**, Prevarskaya N. Comparison of fluorescence probes for intracellular sodium imaging in prostate cancer cell lines. **Eur Biophys J.** **2016** Oct;45(7):765-777. PubMed PMID: 27660079.
35. Gordienko D, Povstyan O, Sukhanova K, Raphaël M, Harhun M, Dyskina Y, **Lehen'kyi V**, Jama A, Lu ZL, Skryma R, Prevarskaya N. Impaired P2X signalling pathways in renal microvascular myocytes in genetic hypertension. **Cardiovasc Res.** **2015** Feb 1;105(2):131-42. doi: 10.1093/cvr/cvu249. Epub 2014 Dec 16. PubMed PMID: 25514930.
34. Raphaël M*, **Lehen'kyi V***, Vandenberghe M*, Beck B, Khalimonchyk S, Vanden Abeele F, Farsetti L, Germain E, Bokhobza A, Mihalache A, Gosset P, Romanin C, Clézardin P, Skryma R, Prevarskaya N. TRPV6 calcium channel translocates to the plasma membrane via Orail-mediated mechanism and controls cancer cell survival. **Proc Natl Acad Sci U S A.** **2014** Aug 29. pii: 201413409.
33. Dubois C*, Vanden Abeele F*, **Lehen'kyi V**, Gkika D, Guarmit B, Lepage G, Slomianny C, Borowiec AS, Bidaux G, Benahmed M, Shuba Y, Prevarskaya N. Remodeling of channel-forming ORAI proteins determines an oncogenic switch in prostate cancer. **Cancer Cell.** **2014** Jul 14;26(1):19-32. doi: 10.1016/j.ccr.2014.04.025.
32. Kondratskyi A, Yassine M, Slomianny C, Kondratska K, Gordienko D, Dewailly E, **Lehen'kyi V**, Skryma R, Prevarskaya N. Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death. **Cell Death Dis.** **2014** Apr 24;5:e1193. doi: 10.1038/cddis.2014.156. PubMed PMID: 24763050.
31. Vandenberghe M*, Raphaël M*, **Lehen'kyi V***, Gordienko D, Hastie R, Oddos T, Rao A, Hogan PG, Skryma R, Prevarskaya N. ORAI1 calcium channel orchestrates skin homeostasis. **Proc Natl Acad Sci U S A.** **2013**, Dec 10;110(50):E4839-48.
30. Oulidi A, Bokhobza A, Gkika D, Vanden Abeele F, **Lehen'kyi V**, Ouafik L, Mauroy B, Prevarskaya N. TRPV2 Mediates Adrenomedullin Stimulation of Prostate and Urothelial Cancer Cell Adhesion, Migration and Invasion. **PLoS One.** **2013** May 31;8(5):e64885.
29. **Lehen'kyi V**, Khalimonchyk S, Pournier A, Raphaël M, Prevarskaya N. Tumor Xenograft Models to Study the Role of TRP Channels in Tumorigenesis. Arpad Szallasi and Tamás Bíró (eds.), TRP Channels in Drug Discovery: Volume II, **Methods in Pharmacology and Toxicology**, **2012**, pp 391-399.
28. **Lehen'kyi V***, Vanoverbergh K*, Thébault S*, Raphaël M*, Vanden Abeele F, Slomianny C, Mariot P, Prevarskaya N. Cytoskeleton Reorganization as an Alternative Mechanism of Store-Operated Calcium Entry Control in Neuroendocrine-Differentiated Cells. **PLoS One.** **2012**;7(9):e45615.

27. **Lehen'kyi V**, Prevarskaya N . TRPV2 (transient receptor potential cation channel, subfamily V, member 2). **Atlas Genet Cytogenet Oncol Haematol**. March **2012**.
URL : <http://AtlasGeneticsOncology.org/Genes/TRPV2ID45817ch17p11.html>
26. **Lehen'kyi V**, Raphaël M, Prevarskaya N. The role of the TRPV6 channel in cancer. **J Physiol**. 2012 Mar 15;590(Pt 6):1369-76. Epub **2012** Feb 13. PubMed PMID: 22331416.
25. **Lehen'kyi V**, Prevarskaya N. Study of TRP Channels in Cancer Cells. In: Zhu MX, Editor. **TRP Channels**. Boca Raton (FL): CRC Press; **2011**. Chapter 17. PubMed PMID: 22593971.
24. **Lehen'kyi V** & Prevarskaya N. TRP-channels and Human Prostate Carcinogenesis. Chapter 7 in **Prostate Cancer - From Bench to Bedside**. Published by INTECH (ISBN 978-953-307-331-6). P. 133-142.
23. **Lehen'kyi V**, Shapovalov G, Skryma R, Prevarskaya N. Ion Channels in Control of Cancer and Cell Apoptosis. **Am J Physiol Cell Physiol**. **2011** Sep 21.
22. Shapovalov G, **Lehen'kyi V**, Skryma R, Prevarskaya N. TRP channels in cell survival and cell death in normal and transformed cells. **Cell Calcium**. **2011** May 29.
21. **Lehen'kyi V***, Raphaël M*, Oulidi A*, Flourakis M, Khalimonchik S, Kondratskyi A, Gordienko DV, Mauroy B, Bonnal JL, Skryma R, Prevarskaya N. TRPV6 Determines the Effect of Vitamin D3 on Prostate Cancer Cell Growth. **PLoS One**. **2011** Feb 11;6(2):e16856.
20. **Lehen'kyi V**, Prevarskaya N. Oncogenic TRP Channels. **Adv Exp Med Biol**. **2011**;704:929-45.
19. **Lehen'kyi V***, Vandenberghe M*, Belaubre F, Julié S, Castex-Rizzi N, Skryma R, Prevarskaya N. Acceleration of keratinocyte differentiation by transient receptor potential vanilloid (TRPV6) channel activation. **J Eur Acad Dermatol Venereol**. **2011** Feb;25 Suppl 1:12-8.
18. **Lehen'kyi V***, M Flourakis*, B Beck, M Raphaël, M Vandenberghe, FV Abeele, M Roudbaraki, G Lepage, B Mauroy, C Romanin, Y Shuba, R Skryma and N Prevarskaya. Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. **Cell Death and Disease** **2010** Sep 16;1(9):e75.
17. **Lehen'kyi V***, Monet M*, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M, Gkika D, Poutier A, Bidaux G, Slomianny C, Delcourt P, Rassendren F, Bergerat JP, Ceraline J, Cabon F, Humez S, Prevarskaya N. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. **Cancer Res**. **2010** Feb 1;70(3):1225-35. Epub 2010 Jan 26.
16. El Hiani Y, Ahidouch A, **Lehen'kyi V**, Hague F, Gouilleux F, Mentaverri R, Kamel S, Lassoued K, Brûlé G, Ouadid-Ahidouch H. Extracellular signal-regulated kinases 1 and 2 and TRPC1 channels are required for calcium-sensing receptor-stimulated MCF-7 breast cancer cell proliferation. **Cell Physiol Biochem** **2009**;23(4-6):335-46.
15. El Hiani Y, **Lehen'kyi V**, Ouadid-Ahidouch H, Ahidouch A. Activation of the calcium-sensing receptor by high calcium induced breast cancer cell proliferation and TRPC1 cation channel over-expression potentially through EGFR pathways. **Arch Biochem Biophys**. **2009** Jun 1;486(1):58-63.

14. Monet M, Gkika D, **Lehen'kyi V**, Pourtier A, Vanden Abeele F, Bidaux G, Juvin V, Rassendren F, Humez S, Prevarsakaya N. Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. **Biochim Biophys Acta**. **2009** Mar;1793(3):528-39.
13. **Lehen'kyi V***, Beck B*, Roudbaraki M, Flourakis M, Charveron M, Bordat P, Polakowska R, Prevarskaya N, Skryma R. TRPC channels determine human keratinocyte differentiation: New insight into basal cell carcinoma. **Cell Calcium**, **2008** May;43(5):492-505. 12. **Lehen'kyi V**, Beck B, Polakowska R, Charveron M, Bordat P, Skryma R, Prevarskaya N. TRPV6 is a Ca²⁺ entry channel essential for Ca²⁺-induced differentiation of human keratinocytes. **J Biol Chem**, **2007** Aug 3;282(31):22582-91.
11. **Lehen'kyi V**, Flourakis M, Skryma R, Prevarskaya N. TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways. **Oncogene**, **2007** Nov 15;26(52):7380-5.
10. Beck B, Zholos A, Sydorenko V, Roudbaraki M, **Lehen'kyi V**, Bordat P, Prevarskaya N, Skryma R. TRPC7 is a receptor-operated DAG-activated channel in human keratinocytes. **J Invest Dermatol**, **2006** Sep;126(9):1982-93. 9. Flourakis M, Van Coppenolle F, **Lehen'kyi V**, Beck B, Skryma R, Prevarskaya N. Passive calcium leak via translocon is a first step for iPLA2-pathway regulated store operated channels activation. **FASEB J**, **2006** Jun;20(8):1215-7. 8. Thebault S, Flourakis M, Vanoverberghe K, Vandermoere F, Roudbaraki M, **Lehen'kyi V**, Slomianny C, Beck B, Mariot P, Bonnal JL, Mauroy B, Shuba Y, Capiod T, Skryma R, Prevarskaya N. Differential role of transient receptor potential channels in Ca²⁺ entry and proliferation of prostate cancer epithelial cells. **Cancer Res**, **2006** Feb 15;66(4):2038-47.
7. **Lehen'kyi V**, Zelensky SN, Stefanov AV. Ca²⁺-sensitivity and cGMP-independent effects of NO in vascular smooth muscle. **Nitric Oxide**, **2005** Mar;12(2):105-13. Erratum in: *Nitric Oxide*. 2005 Sep;13(2):152-3.
6. Soloviev A, **Lehen'kyi V**, Zelensky S, Hellstrand P. Nitric oxide relaxes rat tail artery smooth muscle by cyclic GMP-independent decrease in calcium sensitivity of myofilaments. **Cell Calcium**, **2004** Aug;36(2):165-73.
5. **Lehen'kyi VV**, Zelensky SN, Stefanov AV, Soloviev AI. Effects of nitric oxide donors on vascular smooth muscles depend on a type of vascular smooth-muscle preactivation. **Cardiovasc Toxicol**, **2002**;2(2):151-60.
4. Soloviev AI, **Lehen'kyi VV**, Zelens'kyi SM, Moibenko OO, Stefanov OV. [cGMP-independent effect of nitric oxide on contractility and intracellular calcium level of rat tail artery vascular smooth muscles] **Fiziol Zh**, **2001**;47(3):19-25.
3. Soloviev A., **Lehen'kyi V**, Zelensky S., Stefanov O. Nitroglycerine effect on contractile activity and intracellular calcium level of rat tail artery vascular smooth muscles under the different conditions of pre-activation // **Medical Chemistry**. - **2001**. - V. 3. - №3. - P. 10-13.

2. Soloviev A., **Lehen'kyi V**, Zelensky S., Stefanov O. Method for investigation of contractile activity and intracellular calcium level of vascular smooth muscles in study of calcium sensitivity and screening of cardiovascular drugs // **Acta Medica Leopoliensia**. - **2001**. - №1. - P. 29-34.

1. Soloviev A., **Lehen'kyi V**, Zelensky S., Stefanov O. Effect of nitric oxide and its donors on contractile activity and intracellular calcium level of rat vascular smooth muscles // **Medical Chemistry**. - **2000**. - V. 2. - №4. - P. 9-12.